News articles about Merus Labs International (NASDAQ:MSLI) (TSE:MSL) have trended somewhat positive on Monday, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Merus Labs International earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.3232431435377 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Merus Labs International (NASDAQ MSLI) remained flat at $1.30 during mid-day trading on Monday. 9,409 shares of the company traded hands. Merus Labs International has a one year low of $0.70 and a one year high of $1.33. The company has a 50-day moving average price of $1.20 and a 200 day moving average price of $0.94.

TRADEMARK VIOLATION WARNING: This story was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at

About Merus Labs International

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.

Insider Buying and Selling by Quarter for Merus Labs International (NASDAQ:MSLI)

Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.